Shanghai Bioheart Biological Technology Co Ltd (2185.HK)

Healthcare | Biotechnology
Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$20.9M

Net Income

-$27.2M

Operating Margin

-101.8%

Free Cash Flow

-$167M

Debt / Assets

7.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Shanghai Bioheart Biological Technology Co Ltd (2185.HK).
Income Statement (Quarterly) 2026-04-07 2025-06-30 2025-03-31 2024-12-31
Revenue 20,862,000 20,862,000 10,431,000 0
Cost of Revenue 11,167,000 11,167,000 5,583,500 0
Gross Profit 9,695,000 9,695,000 4,847,500 0
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 10,837,000 10,837,000 5,418,500 6,328,000
Operating Expenses 30,927,000 30,927,000 15,463,500 16,082,500
Operating Income -21,232,000 -21,232,000 -10,616,000 -16,082,500
Interest Expense 0 2,728,000 0 0
Income Before Tax -27,420,000 -27,420,000 -13,710,000 -32,499,499
Income Tax Expense 686,000 686,000 343,000 0
Net Income -27,213,000 -27,213,000 -13,606,500 -31,057,000
Per Share
EPS -0.11 -0.11 -0.06 -0.13
EPS Diluted 0.00 0.00 0.00 0.00